Prevalence and distribution of high-risk human papillomavirus in Greece

European Journal of Cancer Prevention

Volumn 18, Issue 6, 2009, Pages 504-509

  Agorastos, Theodoros ^a   Lambropoulos, Alexandros F ^a   Sotiriadis, Alexandros ^a   Mikos, Themistoklis ^a   Togaridou, Eleonora ^a   Emmanouilides, Christos J ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Greece; Human papillomavirus; Hybrid Capture 2; Polymerase chain reaction; Prevalence

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; FEMALE; GREECE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCREENING TEST; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS TYPING; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GREECE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 70349814393     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32832abd5e     Document Type: Article

References (29)

1. Agorastos T, Bontis J, Lambropoulos AF, Constantinidis TC, Nasioutziki M, Tagou C, Katsouyiannopoulos V (1995). Epidemiology of human papillomavirus infection in Greek asymptomatic women. Eur J Cancer Prev 4:159-167.
2. Agorastos T, Dinas K, Lloveras B, Bosch FX, Kornegay JR, Bontis JN, de Sanjose S (2004). Cervical human papillomavirus infection in women attending gynaecological outpatient clinics in northern Greece. Eur J Cancer Prev 13:145-147.
3. Agorastos T, Dinas K, Lloveras B, de Sanjose S, Kornegay JR, Bonti H (2005). Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecol Oncol 96:714-720.
4. Ault KA (2007). Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861-1868.
5. Brink AA, Snijders PJ, Meijer CJ (2007). HPV detection methods. Dis Markers 23:273-281.
6. Castle PE, Schiffman M, Burk RD,Wacholder S, Hildesheim A, Herrero R, et al. (2002). Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 11: 1394-1399. (Pubitemid 35340375)
7. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. (2005). A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191:1808-1816.
8. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M (2008). Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 46:2595-2604.
9. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM (2005). Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14:1157-1164.
10. De Sanjose S, Almirall R, Lloveras B, Font R, Diaz M, Muntild;oz N, et al. (2003). Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 30:788-793.
11. De Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, Bosch FX (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7:453-459.
12. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. (2000). Improved amplification of genital human papillomaviruses. J Clin Microbiol 38:357-361.
13. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765.
14. Harper DM, Franco EL, Wheeler CM, Ferris DG, Jenkins D, Schuind A, et al. (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255.
15. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. (2000). Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92:464-474.
16. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T (2008). Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 123:1864-1870.
17. Konya J, Veress G, Juhasz A, Szarka K, Sápy T, Herná di Z, Gergely L (2000). Additional human papillomavirus types detected by the hybrid capture tube test among samples from women with cytological and colposcopical atypia. J Clin Microbiol 38:408-411.
18. Kroupis C, Thomopoulou G, Papathomas TG, Vourlidis N, Lazaris AC (2007). Population-based study of human papillomavirus infection and cervical neoplasia in Athens, Greece. Epidemiol Infect 135:943-950.
19. Lungu O,Wright TC Jr, Silverstein S (1992). Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. Mol Cell Probes 6:145-152.
20. Matos E, Loria D, Amestoy GM, Herrera L, Prince MA, Moreno J, et al. (2003). Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 30:593-599.
21. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527. (Pubitemid 36159887)
22. Oh JK, Franceschi S, Kim BK, Kim JY, Ju YH, Hong EK, et al. (2009). Prevalence of human papillomavirus and Chlamydia trachomatis infection among women attending cervical cancer screening in the Republic of Korea. Eur J Cancer Prev 18:56-61.
23. Panotopoulou E, Tserkezoglou A, Kouvousi M, Tsiaousi I, Chatzieleftheriou G, Daskalopoulou D, Magiakos G (2007). Prevalence of human papillomavirus types 6, 11, 16, 18, 31, and 33 in a cohort of Greek women. J Med Virol 79:1898-1905.
24. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. (2005). The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76-84.
25. Stanley M, Lowy DR, Frazer I (2006). Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24 (Suppl 3):S106-S113.
26. Sukvirach S, Smith JS, Tunsakul S, Muntild;oz N, Kesararat V, Opasatian O, et al. (2003). Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 187:1246-1256.
27. Vernon SD, Unger ER, Williams D (2000). Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol 38:651-655.
28. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459-1466.
29. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.